A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

The development and preclinical testing of novel immunotherapy strategies for multiple myeloma can benefit substantially from a humanized animal model that enables quantitative real-time monitoring of tumor progression. This study describes a non-invasive bioluminescent imaging system for real-time monitoring of multiple myeloma cell growth in mice. Background The development and preclinical testing of novel immunotherapy strategies for multiple myeloma can benefit substantially from a humanized animal model that enables quantitative real-time monitoring of tumor progression. Here we have explored the feasibility of establishing such a model in immunodeficient RAG2−/−γc−/− mice, by utilizing non-invasive bioluminescent imaging for real-time monitoring of multiple myeloma cell growth. Design and Methods Seven multiple myeloma cell lines, marked with a green fluorescent protein firefly luciferase fusion gene, were intravenously injected into RAG2−/−γc−/− mice. Tumor localization and outgrowth was monitored by bioluminescent imaging. The sensitivity of this imaging technique was compared to that of free immumoglobulin light chain -based myeloma monitoring. Established tumors were treated with radiotherapy or with allogeneic peripheral blood mononuclear cell infusions to evaluate the application areas of the model. Results Five out of seven tested multiple myeloma cell lines progressed as myeloma-like tumors predominantly in the bone marrow; the two other lines showed additional growth in soft tissues. In our model bioluminescent imaging appeared superior to free light chain-based monitoring and also allowed semi-quantitative monitoring of individual foci of multiple myeloma. Tumors treated with radiotherapy showed temporary regression. However, infusion of allogeneic peripheral blood mononuclear cells resulted in the development of xenogeneic graft-versus-host-disease and a powerful cell dose-dependent graft-versus-myeloma effect, resulting in complete eradication of tumors, depending on the in vitro immunogenicity of the inoculated multiple myeloma cells. Conclusions Our results indicate that this new model allows convenient and sensitive real-time monitoring of cellular approaches for immunotherapy of multiple myeloma-like tumors with different immunogenicities. This model, therefore, allows comprehensive preclinical evaluation of novel combination therapies for multiple myeloma.

[1]  M. Dinauer,et al.  SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. , 2007, Stem cells and development.

[2]  Paul J. Williams,et al.  Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging , 2007, Molecular Cancer Therapeutics.

[3]  N. Munshi,et al.  New drugs for myeloma. , 2007, The oncologist.

[4]  Charles P. Lin,et al.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. , 2007, Blood.

[5]  W. Dalton,et al.  Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma , 2006, Clinical Cancer Research.

[6]  L. Verdonck,et al.  Human Regulatory T Cells Control Xenogeneic Graft-versus-Host Disease Induced by Autologous T Cells in RAG2−/−γc−/− Immunodeficient Mice , 2006, Clinical Cancer Research.

[7]  Yan Tang,et al.  CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice , 2006, Clinical Cancer Research.

[8]  S. Chen‐Kiang,et al.  Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Kimura,et al.  Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. , 2005, Cancer letters.

[10]  I. B. Borel Rinkes,et al.  Validation of bioluminescence imaging of colorectal liver metastases in the mouse. , 2004, The Journal of surgical research.

[11]  Pierfrancesco Tassone,et al.  A clinically relevant SCID-hu in vivo model of human multiple myeloma. , 2004, Blood.

[12]  K. Yata,et al.  The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells , 2004, Leukemia.

[13]  A. Hagenbeek,et al.  Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes. , 2004, Experimental hematology.

[14]  N. Munshi,et al.  Focus on multiple myeloma. , 2004, Cancer cell.

[15]  Z. Paroo,et al.  Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. , 2004, Molecular imaging.

[16]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[17]  S. Hsu,et al.  Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. , 2004, The American journal of pathology.

[18]  Robert M Hoffman,et al.  Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. , 2003, Cancer research.

[19]  A. Hagenbeek,et al.  A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. , 2003, Blood.

[20]  P. Andreotti,et al.  Imaging of luciferase and GFP-transfected human tumours in nude mice. , 2003, Luminescence : the journal of biological and chemical luminescence.

[21]  B. Blom,et al.  Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. , 2002, Blood.

[22]  T. Larson,et al.  Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. , 2002, Clinical chemistry.

[23]  M. V. van Oers,et al.  Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. , 2002, Blood.

[24]  T. Rème,et al.  Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model , 2001, British journal of haematology.

[25]  B. Barlogie,et al.  High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. , 2001, Blood.

[26]  J. Dürig,et al.  Differential expression of chemokine receptors in B cell malignancies , 2001, Leukemia.

[27]  L. Pilarski,et al.  Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. , 2000, Blood.

[28]  H. Clevers,et al.  Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. , 1999, Cancer genetics and cytogenetics.

[29]  R. Day,et al.  Dual-function reporter protein for analysis of gene expression in living cells. , 1998, BioTechniques.

[30]  G. Pinkus,et al.  The development of a model for the homing of multiple myeloma cells to human bone marrow. , 1997, Blood.

[31]  M. Jourdan,et al.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.

[32]  J. Van Dyk,et al.  Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation. , 1994, International journal of radiation oncology, biology, physics.

[33]  R. Weinstein,et al.  An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. , 1993, The American journal of pathology.

[34]  S. Tarui,et al.  Two distinct human myeloma cell lines originating from one patient with myeloma , 1985, International journal of cancer.

[35]  V. Diehl,et al.  Long-term cultivation of plasma cell leukemia cells and autologous lymphoblasts (LCL) in vitro: A comparative study , 1978, Blut.

[36]  D. Jenkins,et al.  Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis , 2004, Clinical & Experimental Metastasis.

[37]  G. Nilsson,et al.  Expression and function of chemokine receptors in human multiple myeloma , 2003, Leukemia.

[38]  B. Barlogie,et al.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. , 1998, Blood.

[39]  S. Wickramasinghe.  Human bone marrow , 1975 .